Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

OP used a finasteride and minoxidil topical spray from HIMS for 11 months with positive results and no side effects. Users discussed the effectiveness, dosages, and alternatives, with many congratulating OP on the impressive progress.

A 28-year-old male experienced hair loss after COVID-19 and used Minoxidil with initial success, but later faced shedding again. He started Finasteride in February 2025, noticing improvements, but recent shedding has caused concern; his regimen includes Minoxidil, microneedling, ketoconazole shampoo, red light therapy, supplements, and a healthy lifestyle.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

The user is happy with their 2-month progress using a 3-in-1 oral tablet containing finasteride, minoxidil, and biotin, with minor side effects like slightly lower libido. They report no significant issues like breakouts and note that oral treatments are more effective than topical ones.

The user is using 5% topical minoxidil, 1mg oral finasteride, biotin, vitamin D, zinc, and microneedling for hair loss. They report no sexual side effects and feel their libido may have increased.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The conversation is about a user sharing their positive hair regrowth progress using 1mg oral finasteride and topical minoxidil. The user encourages others to try treatment early if they are unsure.

The user shared progress photos after using minoxidil 2.5mg and dutasteride 0.5mg daily for hair growth, starting in summer 2024. They reported no noticeable side effects and confirmed androgenetic alopecia in 2024.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

A user shared their 7-month progress using oral minoxidil (2.5mg) and recently started finasteride (1mg) daily, reporting significant hair improvement without side effects. They noticed thicker beard growth and some hair thickening at the crown, with no shedding phase yet.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

A 23-year-old is experiencing hair loss and is considering whether to try oral minoxidil due to fear of side effects, after inconsistent use of topical minoxidil. They are advised to try topical minoxidil consistently first, as it has fewer systemic effects.

_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.

User shared progress pictures after 7 months of using 0.25mg finasteride daily and 1ml minoxidil twice daily, reporting no side effects and being thrilled with the results. Other users discussed the effectiveness of lower doses and the psychological impact of potential side effects.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.